Patricia Andrews
Director/Miembro de la Junta en GLYCOMIMETICS, INC. .
Fortuna: 148 820 $ al 30/04/2024
Cargos activos de Patricia Andrews
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Director/Miembro de la Junta | 12/06/2017 | - |
| Independent Dir/Board Member | 12/06/2017 | - | |
| ONCOLYTICS BIOTECH INC. | Director/Miembro de la Junta | 09/01/2024 | - |
Historial de carrera de Patricia Andrews
Antiguos cargos conocidos de Patricia Andrews.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SUMITOMO PHARMA ONCOLOGY, INC. | Director Ejecutivo | 01/01/2017 | 01/01/2023 |
| INCYTE CORPORATION | Corporate Officer/Principal | 20/10/2008 | 29/08/2012 |
| PFIZER, INC. | Corporate Officer/Principal | 01/10/2008 | 01/10/2008 |
HSBC Bank USA, NA
 HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Corporate Officer/Principal | 01/01/1990 | 01/01/1990 |
| SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | - | - |
Sumitomo Dainippon Pharma Oncology, Inc.
 Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Director Ejecutivo | 01/11/2013 | - |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Director/Miembro de la Junta | 24/04/2017 | - |
| Director Ejecutivo | 24/04/2017 | - | |
| Corporate Officer/Principal | 14/11/2013 | 24/04/2017 |
Formación de Patricia Andrews.
| Brown University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 10 |
| Japón | 2 |
| Canadá | 2 |
Operativa
| Corporate Officer/Principal | 5 |
| Director/Board Member | 3 |
| Chief Executive Officer | 3 |
Sectorial
| Health Technology | 7 |
| Consumer Services | 3 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
HSBC Bank USA, NA
HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Finance |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
| SUMITOMO PHARMA ONCOLOGY, INC. |
- Bolsa de valores
- Insiders
- Patricia Andrews
- Experiencia